Loading
After chemotherapy had failed, pembrolizumab prolonged life compared with docetaxel in lung cancers expressing any PD-L1, with the largest gain in tumours where at least half the cells were positive, and caused fewer severe side effects.
KEYNOTE-010 randomised 1,034 patients with previously treated advanced non-small-cell lung cancer and a PD-L1 tumour proportion score of at least 1% to pembrolizumab at 2 mg/kg or 10 mg/kg or to docetaxel. Both pembrolizumab doses improved overall survival in the whole population and by a larger margin in the group with a score of 50% or more, with fewer grade 3 to 5 treatment-related adverse events than docetaxel. It secured pembrolizumab's regular approval in previously treated lung cancer and established PD-L1 of 1% as the entry threshold for that use.
Alongside the CheckMate trials this study replaced docetaxel with PD-1 blockade as second-line treatment for most lung cancers, and its PD-L1 threshold of 1% became the basis of pembrolizumab's label in previously treated disease.
Shares CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer, KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off, Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable, Randomised trials of stopping immunotherapy after one year versus continuing.
Shares KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off, Roy S. Herbst, Tumour proportion score (TPS), Immunohistochemistry (IHC).
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-1 / PD-L1 immune checkpoint & T-cell activation, Histopathology & immunohistochemistry.
Shares Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable, Randomised trials of stopping immunotherapy after one year versus continuing, Tumour proportion score (TPS), PD-1 / PD-L1 immune checkpoint & T-cell activation.
Shares Tumour proportion score (TPS), Docetaxel, PD-L1, Merck & Co. (MSD).
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-1 / PD-L1 immune checkpoint & T-cell activation, Histopathology & immunohistochemistry.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-1 / PD-L1 immune checkpoint & T-cell activation, Histopathology & immunohistochemistry.
Shares Immunohistochemistry (IHC), PD-1 / PD-L1 immune checkpoint & T-cell activation, Histopathology & immunohistochemistry, PD-L1.